Drugs / CGT003
CGT003
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00086164 | May 2004 → ? | chronic renal failure syndrome, hyperplasia | Anesiva, Inc. | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00041925 | Nov 2001 → Nov 2004 | hyperplasia, limb ischemia, peripheral arterial disease, vascular occlusion disorder | Anesiva, Inc. | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00042081 | Jul 2002 → Feb 2005 | coronary atherosclerosis | Anesiva, Inc. | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CGT003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00041925 ↗ |
| Known as | E2F Decoy | “edifoligide (E2F Decoy)” NCT00086164 ↗ |
| Known as | E2F Duplex Decoy | “CGT003 (E2F Duplex Decoy)” NCT00041925 ↗1“CGT003 (E2F Duplex Decoy)” NCT00042081 ↗ |
| Known as | edifoligide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00086164 ↗ |